相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab
Tjalf Ziemssen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
Michael Guger et al.
JOURNAL OF NEUROLOGY (2019)
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
Cyra E. Leurs et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
Cyra E. Leurs et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis
Brandi Vollmer et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2018)
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
Y. Naegelin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
Veronika Ticha et al.
CLINICAL DRUG INVESTIGATION (2017)
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
Alice Laroni et al.
NEUROLOGICAL SCIENCES (2017)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Tatiana Plavina et al.
NEUROLOGY (2017)
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
Jonathan Alsop et al.
PLOS ONE (2017)
Classifying PML risk with disease modifying therapies
Joseph R. Berger
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
α4-integrin receptor desaturation and disease activity return after natalizumab cessation
Tobias Derfuss et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
Pietro Iaffaldano et al.
BRAIN (2015)
Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
Ludwig Kappos et al.
NEUROLOGY (2015)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Fingolimod after natalizumab and the risk of short-term relapse
Vilija G. Jokubaitis et al.
NEUROLOGY (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient Out Comes (EPOC) study in relapsing multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Explanation and Elaboration
Jan P. Vandenbroucke et al.
EPIDEMIOLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
